Health
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
TOKYO & BASKING RIDGE, N.J., December 22, 2025--DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/40b998b68ef289488beadbdba0aefdf1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yOUoxYrsJyhLLxgsssUaPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/40b998b68ef289488beadbdba0aefdf1","width":480,"height":474}},"lazy":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., December 22, 2025--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) with or without radiotherapy compared to standard of care chemotherapy with or without radiotherapy as an adjuvant treatment (after surgery) in patients with HER2 expressing (IHC 3+/2+) endometrial cancer.","length":395,"tagName":"p"},{"type":"text","content":"DESTINY-Endometrial02 is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F) and the European Network of Gynecological Oncological Trial Groups (ENGOT), with the French cooperative group (GINECO) as the lead ENGOT group.","length":239,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":229,"tagName":"p"},{"type":"text","content":"While surgery is the recommended initial treatment for endometrial cancer, further treatment in the adjuvant setting is determined by the stage of disease and risk of recurrence.1,2 Following current standard of care adjuvant treatment, approximately 39% to 56% of patients with high-risk characteristics will experience disease recurrence or death within 18 months of diagnosis.3 HER2 expression (IHC 3+/2+) is present in approximately 18% to 56% of endometrial cancers and is associated with aggressive disease.4,5,6,7,8 There currently are no HER2 directed medicines approved in the adjuvant setting for HER2 expressing endometrial cancer.9,10","length":646,"tagName":"p"},{"type":"text","content":""Following the positive results of DESTINY-PanTumor02, which included a cohort of patients with metastatic endometrial cancer,...